Clinical Trial Update: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and relatlimab in advanced, microsatellite instability-high cancers that are resistant to prior PD-(L)1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microsatellite Instability-high Cancers
• Mismatch Repair Deficiency Cancers

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING